Long-Term Efficacy and Safety of Mavacamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy: Interim Results from the MAVERICK-LTE Cohort of the MAVA-LTE Study

Anjali Owens,Mark V. Sherrid,Timothy C. Wong,Richard G. Bach,Omar Wever-Pinzon,Marzia Rigolli,Ganesh Balaratnam, Grace Ma, Matthew E. Mealiffe,Jay M. Edelberg

Circulation（2021）

引用 2|浏览5

暂无评分

摘要

Introduction: In the phase 2 MAVERICK-HCM study in patients (pts) with non-obstructive hypertrophic cardiomyopathy (nHCM), mavacamten, a cardiac myosin inhibitor, was well tolerated and associated ...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要